Lyon Street Capital’s Impax Laboratories, Inc. IPXL Stock Holding History

Lyon Street Capital’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-101,773	Closed	-$1.35M	–	52
2016 Q4	$1.35M	Buy	+101,773	New	+$1.74M	0.69%	33
2015 Q3	–	Sell	-48,326	Closed	-$2.22M	–	50
2015 Q2	$2.22M	Buy	+48,326	New	+$2.29M	1.59%	28

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NTC

North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Lyon Street Capital's IPXL Position: Q1 2017 in Review

Lyon Street Capital sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 101,773 shares — an estimated $1.35M sold.

Lyon Street Capital first reported a position in IPXL in Q2 2015 and held it in 2 quarters. The position peaked at $2.22M in Q2 2015. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

Lyon Street Capital reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
Lyon Street Capital sold 101,773 Impax Laboratories, Inc. shares in Q1 2017, an estimated $1.35M.
Lyon Street Capital first reported a position in Impax Laboratories, Inc. in Q2 2015 and held it in 2 quarters.
Lyon Street Capital's Impax Laboratories, Inc. position peaked at $2.22M in Q2 2015.
178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on Lyon Street Capital's 13F filing for Q1 2017, filed 16 May 2017.